This educational program is targeted at physicians and other healthcare providers who specialize in the management of patients with substance use disorders.
Upon completion of this activity, the participants should be bettert able to:
Examine data on the prevalence and transmission of the hepatitis C virus (HCV) in the substance use disorder (SUD) population.
Describe the damaging effects of chronic HCV, thereby emphasizing the need for screening, diagnosis and treatment
Review data on the benefits of treating HCV patients with SUDs, with and without concomitant opioid replacement therapy
Discuss methods to reduce reinfection
Analyze ways to expand the treatment cascade and linkage to care for HCV in the SUD population
Identify challenges faced with regard to HCV care and treatment in SUD patients and recognize the need to prioritize the treatment of HCV in the SUD population
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation (CLDF). The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.5 contact hours may be earned for successful completion of this activity.
Disclosure of Conflicts of Interest
All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. Charles Willis, Director of Continuing Education, consults for Pfizer, Inc., all other staff at the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation (CLDF) have no relationships to disclose.
The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the Annenberg Center for Health Sciences at Eisenhower. The information is presented for the purpose of advancing the attendees' professional development.
Learner Assurance Statement
The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members' significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.
Americans with Disabilities Act
The event staff will be glad to assist you with any special requirements (i.e. physical, dietary, etc.). Please contact us prior to the event at 888-565-5321
For additional educational information or to register online, please visit chronicliverdisease.org.